Breast Implant–Associated Anaplastic Large Cell Lymphoma: Defining Future Research Priorities

Ryan C. DeCoster; Evan B. Lynch; Alisha R. Bonaroti; Roberto N. Miranda; Kelly K. Hunt; Mark W. Clemens

doi:10.1016/j.cps.2020.09.001

Breast Implant–Associated Anaplastic Large Cell Lymphoma: Defining Future Research Priorities

Ryan C. DeCoster, Evan B. Lynch, Alisha R. Bonaroti, Roberto N. Miranda, Kelly K. Hunt, Mark W. Clemens

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging cancer of the immune system that is exclusively associated with textured-surface breast implants. This clinical review provides an update on the diagnosis and management of BIA-ALCL with an emphasis on major advances. The epidemiology and pathophysiology of the disease are also reviewed, focusing on current paradigm shifts and highlighting current controversies related to disease classification and risk mitigation. Finally, the authors conclude by discussing medicolegal and ethical issues surrounding BIA-ALCL while establishing a future basic science and clinical research agenda that is central to improving patient safety.

Original language	English (US)
Pages (from-to)	33-43
Number of pages	11
Journal	Clinics in Plastic Surgery
Volume	48
Issue number	1
DOIs	https://doi.org/10.1016/j.cps.2020.09.001
State	Published - Jan 2021

Keywords

BIA-ALCL
Breast implants
Lymphoma

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.cps.2020.09.001

Cite this

@article{d21055b3127441599ae49a120a218e9b,

title = "Breast Implant–Associated Anaplastic Large Cell Lymphoma: Defining Future Research Priorities",

abstract = "Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging cancer of the immune system that is exclusively associated with textured-surface breast implants. This clinical review provides an update on the diagnosis and management of BIA-ALCL with an emphasis on major advances. The epidemiology and pathophysiology of the disease are also reviewed, focusing on current paradigm shifts and highlighting current controversies related to disease classification and risk mitigation. Finally, the authors conclude by discussing medicolegal and ethical issues surrounding BIA-ALCL while establishing a future basic science and clinical research agenda that is central to improving patient safety.",

keywords = "BIA-ALCL, Breast implants, Lymphoma",

author = "DeCoster, {Ryan C.} and Lynch, {Evan B.} and Bonaroti, {Alisha R.} and Miranda, {Roberto N.} and Hunt, {Kelly K.} and Clemens, {Mark W.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = jan,

doi = "10.1016/j.cps.2020.09.001",

language = "English (US)",

volume = "48",

pages = "33--43",

journal = "Clinics in Plastic Surgery",

issn = "0094-1298",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Breast Implant–Associated Anaplastic Large Cell Lymphoma

T2 - Defining Future Research Priorities

AU - DeCoster, Ryan C.

AU - Lynch, Evan B.

AU - Bonaroti, Alisha R.

AU - Miranda, Roberto N.

AU - Hunt, Kelly K.

AU - Clemens, Mark W.

PY - 2021/1

Y1 - 2021/1

N2 - Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging cancer of the immune system that is exclusively associated with textured-surface breast implants. This clinical review provides an update on the diagnosis and management of BIA-ALCL with an emphasis on major advances. The epidemiology and pathophysiology of the disease are also reviewed, focusing on current paradigm shifts and highlighting current controversies related to disease classification and risk mitigation. Finally, the authors conclude by discussing medicolegal and ethical issues surrounding BIA-ALCL while establishing a future basic science and clinical research agenda that is central to improving patient safety.

AB - Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging cancer of the immune system that is exclusively associated with textured-surface breast implants. This clinical review provides an update on the diagnosis and management of BIA-ALCL with an emphasis on major advances. The epidemiology and pathophysiology of the disease are also reviewed, focusing on current paradigm shifts and highlighting current controversies related to disease classification and risk mitigation. Finally, the authors conclude by discussing medicolegal and ethical issues surrounding BIA-ALCL while establishing a future basic science and clinical research agenda that is central to improving patient safety.

KW - BIA-ALCL

KW - Breast implants

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85096632401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096632401&partnerID=8YFLogxK

U2 - 10.1016/j.cps.2020.09.001

DO - 10.1016/j.cps.2020.09.001

M3 - Review article

C2 - 33220903

AN - SCOPUS:85096632401

SN - 0094-1298

VL - 48

SP - 33

EP - 43

JO - Clinics in Plastic Surgery

JF - Clinics in Plastic Surgery

IS - 1

ER -

Breast Implant–Associated Anaplastic Large Cell Lymphoma: Defining Future Research Priorities

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this